Homeopathy in Oncology Supportive Care: The Pharmacist’s Role in Integrating Patient-Centered Strategies for Chemotherapy-Related Symptom Management (Pharmacy Technician Credit)

Program Description

Chemotherapy can impose a substantial burden on patients with cancer who experience acute and chronic chemotherapy-related adverse events (AEs), including nausea, vomiting, fatigue, and pain. These AEs may occur soon after treatment initiation, leading to dose reductions and treatment delays. Gastrointestinal toxicities remain among the most common chemotherapy-related complications, as nearly one‑third of patients receive highly or moderately emetogenic regimens with rapid-onset nausea and vomiting, and many more experience these symptoms at some point during treatment; these AEs can often persist beyond active treatment, further impairing quality of life. Addressing these AEs may pose particular challenges in patients with cancer who are frail, older, or with polypharmacy for whom standard analgesics, antiemetics, and adjuvant pain therapies may be less tolerated or carry additive risks. It is important for pharmacists and pharmacy technicians to be aware of over-the-counter integrative oncology and homeopathic products since patients and caregivers may actively seek these options for symptom relief as part of supportive cancer care and self-management. This article is designed to equip pharmacists in oncology and community settings with the clinical knowledge, communication skills, and practical strategies needed to evaluate chemotherapy-related symptom burden, discuss integrative options such as homeopathy in an evidence-informed manner, and optimize patient-centered supportive care. Pharmacists and pharmacy technicians will examine chemotherapy-related AEs and integrative options to support patients and caregivers in shared decision-making regarding symptom management with realistic expectations on the safe use of homeopathic therapies.

Target audience: Community and Oncology pharmacists
Type of activity: Application
Release date: April 28,2026
Expiration date: April 28, 2028
Learner level: Foundational, Intermediate, Advanced
Time to complete activity: 2.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Indicate common chemotherapy-related adverse effects, as well as the regulatory status and role of homeopathic medications
2. Discuss potential uses and safety considerations of homeopathic medications in oncology treatment plans
3. Recall strategies for pharmacy technicians to support pharmacists, patients with cancer and caregivers with the use of homeopathic therapies for symptom management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity numbers 0290-0000-26-097-H99-P and 0290-0000-26-097-H99-T. The activity is available for CE credit through April 28, 2028

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Megan May, Pharm.D., BCOP, FHOPA, FAPO has the following relevant financial relationships with ineligible companies to disclose:

Medical Writing and Editorial Support

Consultant: Amgen, DSI

Speaker’s Bureau: Amgen, Abbvie, Genmab, Pharmacosmus, AZ

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD, RPh; Macara Desai ; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms